A recent study from the Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland shows that “GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.” This study was published in the 29 July 2014 issue of the Journal “Cell Metabolism” (the no.1 journal in Metabolism; and I.F: 16.747) by Prof. Etienne Meylan, Masin M and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based antimetastasis therapy: AMPKα2 inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3.
Significance: The study presented here suggests, for the first time, that AMPKα2, by suppressing the expression of its target gene, it may decrease the expression of GLUT3. Thereby, it may inhibit glycolysis. Thus, pharmacological formulations encompassing “AMPKα2 activators” may be used to stall the progression of invasive human tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Web: http://genomediscovery.org
Citation: Boominathan, MiRNA-based antimetastasis therapy: AMPKα2 inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3, 27/March/2015, 22.26, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Undisclosed information: How AMPKα2 suppresses the expression of GLUT3
* Research cooperation
